Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,654 across all filing types
Latest filing 2025-05-23 Capital/Financing Update
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Memorandum of Understanding/Agreements
Capital/Financing Update Classification · 95% confidence The document is an intimation to stock exchanges under Regulation 30 of the SEBI Listing Regulations, dated May 23, 2025. It details the approval by the Finance Committee of the Board of Directors for availing working capital demand loan facility, packing credit facility, and post shipment facility from Qatar National Bank amounting to Rs. 50 Crores. The document includes specifics of the loan agreements, interest rates, tenure, repayment terms, security provided, and personal guarantee by the promoter. There are no financial statements or comprehensive financial analysis present. The document is a regulatory announcement about financing arrangements and capital structure changes, not a full financial report or earnings release. Therefore, it fits best under Capital/Financing Update (CAP). The document length (8219 characters) supports it being a detailed announcement rather than a brief notice or a full report.
2025-05-23 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of an analyst/investor conference call for Morepen Laboratories Limited discussing the Q4 and full fiscal year 2025 financial results. It includes detailed management commentary on business segments, product lines, market share, and financial performance. The text explicitly mentions it is a transcript of the Q4 FY '25 Results Conference Call held on May 13, 2025. The content is a full text of the call including management remarks and Q&A format, typical of earnings call transcripts. Therefore, the document fits the category of a Call Transcript (CT). The document length is substantial (15,000 characters), and it contains the full transcript, not just an announcement or summary, confirming it is not an Earnings Release (ER) or Report Publication Announcement (RPA).
2025-05-17 English
Please find attached Transcript of Analyst/Investors Conference Call- Q4 FY 25
Call Transcript Classification · 100% confidence The document is a transcript of an analyst/investor conference call for Morepen Laboratories Limited discussing the Q4 and full fiscal year 2025 financial results. It includes detailed management commentary on business segments, product lines, market share, and financial performance. The text explicitly states it is a transcript of the Q4 FY25 results conference call held on May 13, 2025. The content includes management remarks, financial data, and Q&A format typical of earnings call transcripts. It is not a brief announcement, regulatory filing, or a report publication notice. Therefore, the document fits the definition of a Call Transcript (CT).
2025-05-17 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges regarding the availability of an audio recording of an Analyst/Investors Conference Call held on May 13, 2025, discussing audited financial results for the quarter and financial year ended March 31, 2025. It references Regulation 30 of the SEBI Listing Regulations, which pertains to disclosure requirements. The document does not contain the transcript itself, financial data, or detailed analysis, but rather informs about the availability of the audio recording on the company's website. The document length is only 1835 characters, indicating it is a brief announcement rather than a full report or transcript. According to the rules, such announcements about availability of conference call recordings should be classified as Regulatory Filings (RNS) because it is a general regulatory announcement and does not contain the full transcript or detailed financial data.
2025-05-13 English
Please find enclosed weblink of audio recording of Investor conference call on Q4 FY 25.
Regulatory Filings Classification · 95% confidence The document is a short communication addressed to stock exchanges regarding the availability of an audio recording of an analyst/investor conference call held on May 13, 2025. It references the conference call discussing audited financial results for the quarter and financial year ended March 31, 2025. The document does not contain the transcript itself, financial data, or detailed analysis, but rather informs about the availability of the audio recording. The length is only 1835 characters, which is quite short and fits the pattern of an announcement rather than a full report or transcript. According to the classification rules, such announcements about conference calls or their recordings are best classified as Call Transcript (CT) if the transcript is included, but since this is only an announcement of the audio recording availability, it is more appropriate to classify it as Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories. Therefore, the correct classification is Regulatory Filings (RNS) with high confidence.
2025-05-13 English
Please find attached newspaper advertisements
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) regarding the publication of audited standalone and consolidated financial results for the quarter and financial year ended 31 March 2025. It mentions that these financial results were approved by the Board of Directors on 12 May 2025 and published in newspapers on 13 May 2025. The document includes newspaper advertisements of these financial results and states compliance with SEBI regulations. The document is essentially an announcement of the publication of the audited financial results, not the full financial report itself. The length is under 10,000 characters, and it primarily serves to notify the stock exchanges and public about the publication of the financial results. Therefore, according to the "Menu vs Meal" rule, this document is a Report Publication Announcement (RPA), not the full Annual Report or Interim Report.
2025-05-13 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.